ID   SUM52PE GDC-0941_resistant
AC   CVCL_A1FM
DR   cancercelllines; CVCL_A1FM
DR   Cosmic; 2787233
DR   Wikidata; Q102114951
RX   PubMed=26759240;
CC   Selected for resistance to: ChEBI; CHEBI:65326; Pictrelisib (Pictilisib; GDC-0941).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68Val (c.203C>T); ClinVar=VCV000406701; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3425 ! SUM52PE
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 6
//
RX   PubMed=26759240; DOI=10.1158/0008-5472.CAN-15-2201;
RA   Nakanishi Y., Walter K., Spoerke J.M., O'Brien C., Huw L.Y.,
RA   Hampton G.M., Lackner M.R.;
RT   "Activating mutations in PIK3CB confer resistance to PI3K inhibition
RT   and define a novel oncogenic role for p110beta.";
RL   Cancer Res. 76:1193-1203(2016).
//